Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response

• Published in: Nature communications Vol. 15; no. 1; pp. 5442 - 18
• Main Authors: Webb, Mason J., Sangsuwannukul, Thanich, van Vloten, Jacob, Evgin, Laura, Kendall, Benjamin, Tonne, Jason, Thompson, Jill, Metko, Muriel, Moore, Madelyn, Chiriboga Yerovi, Maria P., Olin, Michael, Borgatti, Antonella, McNiven, Mark, Monga, Satdarshan P. S., Borad, Mitesh J., Melcher, Alan, Roberts, Lewis R., Vile, Richard
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.06.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 13/21; 13/31; 13/51; 42/40; 631/250/2152/1566/1618; 631/250/2520; 631/67/1059/2325; 631/67/1504/1610/4029; 64/60; Animals; Antigen (tumor-associated); Antigens; Antigens, Neoplasm - immunology; Antiviral agents; Antiviral drugs; B7-H1 Antigen - genetics; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - therapy; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Cell activation; Cell Line, Tumor; Cytometry; Disease resistance; Effector cells; Female; Hepatocellular carcinoma; Humanities and Social Sciences; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunogenicity; Inflammation; Interferon-beta - immunology; Interferon-beta - metabolism; Liver cancer; Liver Neoplasms - immunology; Liver Neoplasms - therapy; Lymphocytes; Lymphocytes T; Mice; Mice, Inbred C57BL; Microenvironments; multidisciplinary; Oncolysis; Oncolytic Virotherapy - methods; Oncolytic Viruses - genetics; Oncolytic Viruses - immunology; PD-L1 protein; Populations; Science; Science (multidisciplinary); Stomatitis; T-Lymphocytes - immunology; Therapy; Tumor microenvironment; Tumor Microenvironment - immunology; Tumors; Vesiculovirus - genetics; Vesiculovirus - immunology; Viruses; β-Interferon

Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC). Since oncolytic viruses (OV) can generate a highly immune-...